Dr Dennis Wright, CLINUVEL’s Chief Scientific Officer, presented on the Company’s vitiligo program at the Capital Markets Briefing that took place in Sydney in May. He explained the rationale behind the clinical endpoints, as well as the program’s pathway to market.
The full slide deck is available on clinuvel.com.